Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo Controlled Dose-ranging Study to Determine the Effect on MRI Lesions and Safety of A4I Antagonist in Relapsing Multiple Sclerosis.

NCT00104143 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00104143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00104143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo Controlled Dose-ranging Study to Determine the Effect on MRI Lesions and Safety of A4I Antagonist in Relapsing Multiple Sclerosis.
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Withdrawn
Start date
October 31, 2007
Completion date
Not reported
Enrollment
0 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis